help button home button Am J Pathol Epitomics, Inc.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tian, Q.
Right arrow Articles by Moskaluk, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tian, Q.
Right arrow Articles by Moskaluk, C. A.
(American Journal of Pathology. 1999;154:1643-1647.)
© 1999 American Society for Investigative Pathology

Short Communication

Activating c-kit Gene Mutations in Human Germ Cell Tumors

Qingsheng Tian*, Henry F. Frierson, Jr.*, Geoffrey W. Krystal{dagger} and Christopher A. Moskaluk*{ddagger}

Departments of Pathology*
and Biochemistry and Molecular Genetics,{ddagger}
University of Virginia Health Sciences Center, Charlottesville, and Department of Medicine,{dagger}
Medical College of Virginia Commonwealth University, McGuire Veterans Affairs Medical Center, Richmond, Virginia

The c-kit gene encodes a tyrosine kinase receptor (KIT) that is required in normal spermatogenesis and is expressed in seminomas and dysgerminomas, a subset of human germ cell tumors (GCTs). To determine whether activating mutations of the c-kit gene occur in GCTs, primary tissue samples of 33 testicular and ovarian tumors were examined for mutations in the juxtamembrane and phosphotransferase domains by polymerase chain reaction amplification and DNA sequencing. A novel missense mutation (D816H) was found in the phosphotransferase domain in tumors of seminoma/dysgerminoma differentiation. The c-kit alleles in nonneoplastic tissues from these patients were wild type, suggesting that the mutant alleles were acquired and selected for during malignant transformation. In cell transfection experiments, the D816H mutant protein was a constitutively activated kinase and was constitutively phosphorylated on tyrosine residues. This is the first description of an activating c-kit mutation in GCTs and is evidence that the KIT signal transduction pathway is important in the pathogenesis of neoplasms with seminoma differentiation.




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
J. Sun, M. Pedersen, and L. Ronnstrand
The D816V Mutation of c-Kit Circumvents a Requirement for Src Family Kinases in c-Kit Signal Transduction
J. Biol. Chem., April 24, 2009; 284(17): 11039 - 11047.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
D. PECTASIDES, G. PAPAXOINIS, M. NIKOLAOU, C. VALAVANIS, G. ARAVANTINOS, G. FOUNTZILAS, N. TAMVAKIS, E. PECTASIDES, I. LEKKA, P. ARAPANTONI-DADIOTI, et al.
Analysis of 7 Immunohistochemical Markers in Male Germ Cell Tumors Demonstrates the Prognostic Significance of p53 and MIB-1
Anticancer Res, February 1, 2009; 29(2): 737 - 744.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
D. R. Feldman, G. J. Bosl, J. Sheinfeld, and R. J. Motzer
Medical Treatment of Advanced Testicular Cancer
JAMA, February 13, 2008; 299(6): 672 - 684.
[Abstract] [Full Text] [PDF]

Home page
 Br J OphthalmolHome page
R. J Barry, L. R de Moura, J.-C. Marshall, B. F Fernandes, M. E. Orellana, E. Antecka, C. Martins, and M. N Burnier
Expression of C-kit in retinoblastoma: a potential therapeutic target
Br J Ophthalmol, November 1, 2007; 91(11): 1532 - 1536.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Voisset, S. Lopez, P. Dubreuil, and P. De Sepulveda
The tyrosine kinase FES is an essential effector of KITD816V proliferation signal
Blood, October 1, 2007; 110(7): 2593 - 2599.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
V. Munugalavadla, E. C. Sims, J. Borneo, R. J. Chan, and R. Kapur
Genetic and pharmacologic evidence implicating the p85{alpha}, but not p85{beta}, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis
Blood, September 1, 2007; 110(5): 1612 - 1620.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. S. Rosen, R. Kurzrock, M. Mulay, A. Van Vugt, M. Purdom, C. Ng, J. Silverman, A. Koutsoukos, Y.-N. Sun, M. B. Bass, et al.
Safety, Pharmacokinetics, and Efficacy of AMG 706, an Oral Multikinase Inhibitor, in Patients With Advanced Solid Tumors
J. Clin. Oncol., June 10, 2007; 25(17): 2369 - 2376.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. C. Heinrich, C. L. Corless, C. D. Blanke, G. D. Demetri, H. Joensuu, P. J. Roberts, B. L. Eisenberg, M. von Mehren, C. D.M. Fletcher, K. Sandau, et al.
Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors
J. Clin. Oncol., October 10, 2006; 24(29): 4764 - 4774.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. A. Curtin, K. Busam, D. Pinkel, and B. C. Bastian
Somatic Activation of KIT in Distinct Subtypes of Melanoma
J. Clin. Oncol., September 10, 2006; 24(26): 4340 - 4346.
[Abstract] [Full Text] [PDF]

Home page
 GENES CELLSHome page
B. Wang, J. Tsukada, T. Higashi, T. Mizobe, A. Matsuura, F. Mouri, N. Sawamukai, C. Ra, and Y. Tanaka
Growth suppression of human mast cells expressing constitutively active c-kit receptors by JNK inhibitor SP600125.
Genes Cells, September 1, 2006; 11(9): 983 - 992.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Paschka, G. Marcucci, A. S. Ruppert, K. Mrozek, H. Chen, R. A. Kittles, T. Vukosavljevic, D. Perrotti, J. W. Vardiman, A. J. Carroll, et al.
Adverse Prognostic Significance of KIT Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B Study
J. Clin. Oncol., August 20, 2006; 24(24): 3904 - 3911.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. B. Sambol, G. Ambrosini, R. C. Geha, P. T. Kennealey, P. DeCarolis, R. O'Connor, Y. V. Wu, M. Motwani, J.-H. Chen, G. K. Schwartz, et al.
Flavopiridol Targets c-KIT Transcription and Induces Apoptosis in Gastrointestinal Stromal Tumor Cells
Cancer Res., June 1, 2006; 66(11): 5858 - 5866.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
E. Rajpert-De Meyts
Developmental model for the pathogenesis of testicular carcinoma in situ: genetic and environmental aspects
Hum. Reprod. Update, May 1, 2006; 12(3): 303 - 323.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. M. Schittenhelm, S. Shiraga, A. Schroeder, A. S. Corbin, D. Griffith, F. Y. Lee, C. Bokemeyer, M. W.N. Deininger, B. J. Druker, and M. C. Heinrich
Dasatinib (BMS-354825), a Dual SRC/ABL Kinase Inhibitor, Inhibits the Kinase Activity of Wild-Type, Juxtamembrane, and Activation Loop Mutant KIT Isoforms Associated with Human Malignancies
Cancer Res., January 1, 2006; 66(1): 473 - 481.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
J. P. Zappulla, P. Dubreuil, S. Desbois, S. Letard, N. B. Hamouda, M. Daeron, G. Delsol, M. Arock, and R. S. Liblau
Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation
J. Exp. Med., December 19, 2005; 202(12): 1635 - 1641.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. P. Rubin, C. R. Antonescu, J. P. Scott-Browne, M. L. Comstock, Y. Gu, M. R. Tanas, C. B. Ware, and J. Woodell
A Knock-In Mouse Model of Gastrointestinal Stromal Tumor Harboring Kit K641E
Cancer Res., August 1, 2005; 65(15): 6631 - 6639.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
K. Nakagawa, Y. Matsuno, H. Kunitoh, A. Maeshima, H. Asamura, and R. Tsuchiya
Immunohistochemical KIT (CD117) Expression in Thymic Epithelial Tumors
Chest, July 1, 2005; 128(1): 140 - 144.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. I. Skotheim, G. E. Lind, O. Monni, J. M. Nesland, V. M. Abeler, S. D. Fossa, N. Duale, G. Brunborg, O. Kallioniemi, P. W. Andrews, et al.
Differentiation of Human Embryonal Carcinomas In vitro and In vivo Reveals Expression Profiles Relevant to Normal Development
Cancer Res., July 1, 2005; 65(13): 5588 - 5598.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Entz-Werle, L. Marcellin, M.-P. Gaub, E. Guerin, A. Schneider, P. Berard-Marec, C. Kalifa, L. Brugiere, H. Pacquement, C. Schmitt, et al.
Prognostic Significance of Allelic Imbalance at the c-kit Gene Locus and c-kit Overexpression by Immunohistochemistry in Pediatric Osteosarcomas
J. Clin. Oncol., April 1, 2005; 23(10): 2248 - 2255.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Jelacic and D. Linnekin
PKC{delta} plays opposite roles in growth mediated by wild-type Kit and an oncogenic Kit mutant
Blood, March 1, 2005; 105(5): 1923 - 1929.
[Abstract] [Full Text] [PDF]

Home page
 GeneticsHome page
H.-B. Ruan, N. Zhang, and X. Gao
Identification of a Novel Point Mutation of Mouse Proto-Oncogene c-kit Through N-Ethyl-N-nitrosourea Mutagenesis
Genetics, February 1, 2005; 169(2): 819 - 831.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. Sihto, M. Sarlomo-Rikala, O. Tynninen, M. Tanner, L. C. Andersson, K. Franssila, N. N. Nupponen, and H. Joensuu
KIT and Platelet-Derived Growth Factor Receptor Alpha Tyrosine Kinase Gene Mutations and KIT Amplifications in Human Solid Tumors
J. Clin. Oncol., January 1, 2005; 23(1): 49 - 57.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Th. Went, S. Dirnhofer, M. Bundi, M. Mirlacher, P. Schraml, S. Mangialaio, S. Dimitrijevic, J. Kononen, A. Lugli, R. Simon, et al.
Prevalence of KIT Expression in Human Tumors
J. Clin. Oncol., November 15, 2004; 22(22): 4514 - 4522.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
F. Chiara, M.-J. Goumans, H. Forsberg, A. Ahgren, A. Rasola, P. Aspenstrom, C. Wernstedt, C. Hellberg, C.-H. Heldin, and R. Heuchel
A Gain of Function Mutation in the Activation Loop of Plateletderived Growth Factor {beta}-Receptor Deregulates Its Kinase Activity
J. Biol. Chem., October 8, 2004; 279(41): 42516 - 42527.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. L. Corless, J. A. Fletcher, and M. C. Heinrich
Biology of Gastrointestinal Stromal Tumors
J. Clin. Oncol., September 15, 2004; 22(18): 3813 - 3825.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. D. Mol, D. R. Dougan, T. R. Schneider, R. J. Skene, M. L. Kraus, D. N. Scheibe, G. P. Snell, H. Zou, B.-C. Sang, and K. P. Wilson
Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase
J. Biol. Chem., July 23, 2004; 279(30): 31655 - 31663.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. Lefevre, A.-L. Glotin, A. Calipel, F. Mouriaux, T. Tran, Z. Kherrouche, C.-A. Maurage, C. Auclair, and F. Mascarelli
Roles of Stem Cell Factor/c-Kit and Effects of Glivec(R)/STI571 in Human Uveal Melanoma Cell Tumorigenesis
J. Biol. Chem., July 23, 2004; 279(30): 31769 - 31779.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
C. All-Ericsson, L. Girnita, A. Muller-Brunotte, B. Brodin, S. Seregard, A. Ostman, and O. Larsson
c-Kit-Dependent Growth of Uveal Melanoma Cells: A Potential Therapeutic Target?
Invest. Ophthalmol. Vis. Sci., July 1, 2004; 45(7): 2075 - 2082.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Boldrini, S. Ursino, S. Gisfredi, P. Faviana, V. Donati, T. Camacci, M. Lucchi, A. Mussi, F. Basolo, R. Pingitore, et al.
Expression and Mutational Status of c-kit in Small-Cell Lung Cancer: Prognostic Relevance
Clin. Cancer Res., June 15, 2004; 10(12): 4101 - 4108.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
X Tang, M Boxer, A Drummond, P Ogston, M Hodgins, and A D Burden
A germline mutation in KIT in familial diffuse cutaneous mastocytosis
J. Med. Genet., June 1, 2004; 41(6): e88 - e88.
[Full Text] [PDF]

Home page
 BloodHome page
C. Akin, G. Fumo, A. S. Yavuz, P. E. Lipsky, L. Neckers, and D. D. Metcalfe
A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib
Blood, April 15, 2004; 103(8): 3222 - 3225.
[Abstract] [Full Text] [PDF]

Home page
 INT J SURG PATHOLHome page
J. L. Hornick and C. D. M. Fletcher
The Significance of KIT (CD117) in Gastrointestinal Stromal Tumors
International Journal of Surgical Pathology, April 1, 2004; 12(2): 93 - 97.
[PDF]

Home page
 JCOHome page
D. W. Sternberg and D. G. Gilliland
The Role of Signal Transducer and Activator of Transcription Factors in Leukemogenesis
J. Clin. Oncol., January 15, 2004; 22(2): 361 - 371.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Gonzalez, E. J. Andreu, A. Panizo, S. Inoges, A. Fontalba, J. L. Fernandez-Luna, M. Gaboli, L. Sierrasesumaga, S. Martin-Algarra, J. Pardo, et al.
Imatinib Inhibits Proliferation of Ewing Tumor Cells Mediated by the Stem Cell Factor/KIT Receptor Pathway, and Sensitizes Cells to Vincristine and Doxorubicin-Induced Apoptosis
Clin. Cancer Res., January 15, 2004; 10(2): 751 - 761.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
K. Kemmer, C. L. Corless, J. A. Fletcher, L. McGreevey, A. Haley, D. Griffith, O. W. Cummings, C. Wait, A. Town, and M. C. Heinrich
KIT Mutations Are Common in Testicular Seminomas
Am. J. Pathol., January 1, 2004; 164(1): 305 - 313.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. H. J. Looijenga, H. de Leeuw, M. van Oorschot, R. J. H. L. M. van Gurp, H. Stoop, A. J. M. Gillis, C. A. de Gouveia Brazao, R. F. A. Weber, W. J. Kirkels, T. van Dijk, et al.
Stem Cell Factor Receptor (c-KIT) Codon 816 Mutations Predict Development of Bilateral Testicular Germ-Cell Tumors
Cancer Res., November 15, 2003; 63(22): 7674 - 7678.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. D. Mol, K. B. Lim, V. Sridhar, H. Zou, E. Y. T. Chien, B.-C. Sang, J. Nowakowski, D. B. Kassel, C. N. Cronin, and D. E. McRee
Structure of a c-Kit Product Complex Reveals the Basis for Kinase Transactivation
J. Biol. Chem., August 22, 2003; 278(34): 31461 - 31464.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Shivakrupa, A. Bernstein, N. Watring, and D. Linnekin
Phosphatidylinositol 3'-Kinase Is Required for Growth of Mast Cells Expressing the Kit Catalytic Domain Mutant
Cancer Res., August 1, 2003; 63(15): 4412 - 4419.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. R. Antonescu, G. Sommer, L. Sarran, S. J. Tschernyavsky, E. Riedel, J. M. Woodruff, M. Robson, R. Maki, M. F. Brennan, M. Ladanyi, et al.
Association of KIT Exon 9 Mutations with Nongastric Primary Site and Aggressive Behavior: KIT Mutation Analysis and Clinical Correlates of 120 Gastrointestinal Stromal Tumors
Clin. Cancer Res., August 1, 2003; 9(9): 3329 - 3337.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. Sommer, V. Agosti, I. Ehlers, F. Rossi, S. Corbacioglu, J. Farkas, M. Moore, K. Manova, C. R. Antonescu, and P. Besmer
Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase
PNAS, May 27, 2003; 100(11): 6706 - 6711.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Scotlandi, M. C. Manara, R. Strammiello, L. Landuzzi, S. Benini, S. Perdichizzi, M. Serra, A. Astolfi, G. Nicoletti, P.-L. Lollini, et al.
c-kit Receptor Expression in Ewing's Sarcoma: Lack of Prognostic Value but Therapeutic Targeting Opportunities in Appropriate Conditions
J. Clin. Oncol., May 15, 2003; 21(10): 1952 - 1960.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
M. C. Heinrich, C. L. Corless, A. Duensing, L. McGreevey, C.-J. Chen, N. Joseph, S. Singer, D. J. Griffith, A. Haley, A. Town, et al.
PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
Science, January 31, 2003; 299(5607): 708 - 710.
[Abstract] [Full Text] [PDF]

Home page
 Veterinary PathologyHome page
D. Frost, J. Lasota, and M. Miettinen
Gastrointestinal Stromal Tumors and Leiomyomas in the Dog: A Histopathologic, Immunohistochemical, and Molecular Genetic Study of 50 Cases
Veterinary Pathology, January 1, 2003; 40(1): 42 - 54.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. J. Frost, P. T. Ferrao, T. P. Hughes, and L. K. Ashman
Juxtamembrane Mutant V560GKit Is More Sensitive to Imatinib (STI571) Compared with Wild-Type c-Kit Whereas the Kinase Domain Mutant D816VKit Is Resistant
Mol. Cancer Ther., October 1, 2002; 1(12): 1115 - 1124.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
A. V. Moses, M. A. Jarvis, C. Raggo, Y. C. Bell, R. Ruhl, B. G. M. Luukkonen, D. J. Griffith, C. L. Wait, B. J. Druker, M. C. Heinrich, et al.
Kaposi's Sarcoma-Associated Herpesvirus-Induced Upregulation of the c-kit Proto-Oncogene, as Identified by Gene Expression Profiling, Is Essential for the Transformation of Endothelial Cells
J. Virol., August 15, 2002; 76(16): 8383 - 8399.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. C. Heinrich, C. D. Blanke, B. J. Druker, and C. L. Corless
Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive Malignancies
J. Clin. Oncol., March 15, 2002; 20(6): 1692 - 1703.
[Abstract] [Full Text] [PDF]

Home page
 INT J SURG PATHOLHome page
S. K. Tickoo, B. Hutchinson, J. Bacik, M. Mazumdar, R. J. Motzer, D. F. Bajorin, G. J. Bosl, and V. E. Reuter
Testicular Seminoma: A Clinicopathologic and Immunohistochemical Study of 105 Cases with Special Reference to Seminomas with Atypical Features
International Journal of Surgical Pathology, January 1, 2002; 10(1): 23 - 32.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Scappini, F. Onida, H. M. Kantarjian, L. Dong, S. Verstovsek, M. J. Keating, and M. Beran
Effects of Signal Transduction Inhibitor 571 in Acute Myelogenous Leukemia Cells
Clin. Cancer Res., December 1, 2001; 7(12): 3884 - 3893.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. P. Rubin, S. Singer, C. Tsao, A. Duensing, M. L. Lux, R. Ruiz, M. K. Hibbard, C.-J. Chen, S. Xiao, D. A. Tuveson, et al.
KIT Activation Is a Ubiquitous Feature of Gastrointestinal Stromal Tumors
Cancer Res., November 1, 2001; 61(22): 8118 - 8121.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. Chian, S. Young, A. Danilkovitch-Miagkova, L. Ronnstrand, E. Leonard, P. Ferrao, L. Ashman, and D. Linnekin
Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant
Blood, September 1, 2001; 98(5): 1365 - 1373.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Z.-Q. Ning, J. Li, and R. J. Arceci
Signal transducer and activator of transcription 3 activation is required for Asp816 mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells
Blood, June 1, 2001; 97(11): 3559 - 3567.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. W. Krystal, S. Honsawek, D. Kiewlich, C. Liang, S. Vasile, L. Sun, G. McMahon, and K. E. Lipson
Indolinone Tyrosine Kinase Inhibitors Block Kit Activation and Growth of Small Cell Lung Cancer Cells
Cancer Res., May 1, 2001; 61(9): 3660 - 3668.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. Buchdunger, C. L. Cioffi, N. Law, D. Stover, S. Ohno-Jones, B. J. Druker, and N. B. Lydon
Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors
J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 139 - 145.
[Abstract] [Full Text]

Home page
 Am. J. Pathol.Home page
J. Lasota, A. Wozniak, M. Sarlomo-Rikala, J. Rys, R. Kordek, A. Nassar, L. H. Sobin, and M. Miettinen
Mutations in Exons 9 and 13 of KIT Gene Are Rare Events in Gastrointestinal Stromal Tumors : A Study of 200 Cases
Am. J. Pathol., October 1, 2000; 157(4): 1091 - 1095.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
B. Lawrence, A. Perez-Atayde, M. K. Hibbard, B. P. Rubin, P. Dal Cin, J. L. Pinkus, G. S. Pinkus, S. Xiao, E. S. Yi, C. D. M. Fletcher, et al.
TPM3-ALK and TPM4-ALK Oncogenes in Inflammatory Myofibroblastic Tumors
Am. J. Pathol., August 1, 2000; 157(2): 377 - 384.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. C. Heinrich, D. J. Griffith, B. J. Druker, C. L. Wait, K. A. Ott, and A. J. Zigler
Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor
Blood, August 1, 2000; 96(3): 925 - 932.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. L. Lux, B. P. Rubin, T. L. Biase, C.-J. Chen, T. Maclure, G. Demetri, S. Xiao, S. Singer, C. D.M. Fletcher, and J. A. Fletcher
KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal Tumors
Am. J. Pathol., March 1, 2000; 156(3): 791 - 795.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Society for Investigative Pathology.